摘要
目的探讨重组人生长激素对矮小症患儿身高增长的影响因素,为进一步制定重组人生长激素（recombinant human growth hormone,rhGH）治疗方案提供依据。方法以rhGH治疗时间超过6个月-2年的103例矮小症患儿为对象,将治疗后身高增长（Y）设为因变量,以年龄,身高,体重,靶身高,身高标准差分值,骨龄,父亲身高,母亲身高,实际年龄（CA）-骨龄（bone age,BA）,BA/CA,生长激素峰值,治疗时间和诊断作为自变量,采用多元逐步回归分析,评价影响rhGH治疗对身高增长疗效的因素。结果多元线性回归分析结果显示,rhGH治疗后身高增长与治疗前患儿身高呈负相关,与治疗时间,遗传靶身高,父亲身高,BA与CA的差值与疗效呈正相关。结论骨龄落后的程度、开始治疗时身高、靶身高可作为预测rhGH增高疗效的指标之一。
Objective To analyze the correlative factors that affect efficacy of recombinant human growth hormone（rhGH）treatment in short stature children. Methods Multivariate linear regression analysis were performed to assess factors related to rhGH treatment curative effect on height growth by 103 cases of short stature children with rhGH treatment for more than 6months to 2years.In the study the height growth after rhGH treatment was the dependent variable（Y）,and age,height,weight,target height,height standard deviation score,bone age,height,father height,mother height,age（CA）-bone age（BA）,BA/CA,growth hormone peak,treatment time and diagnosis were independent variables. Result Multiple liner regression analysis showed that height growth of children with rhGH treatment was negatively correlated with their height before treatment,and positively correleted with treatment time,target heigh,father height and CA-BA. Conclusion Retardation of bone age,heigh at the start of treatment,and target height can be used for forecasting indicators of height growth of children with rhGH treatment.
出处
《中国儿童保健杂志》
CAS
2015年第2期147-149,152,共4页
Chinese Journal of Child Health Care
关键词
矮小儿童
重组人生长激素
疗效
影响因素
short stature children
recombinant human growth hormone
curative effect
correlative factors
